{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:16:13Z","timestamp":1791252973061,"version":"4.1.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1038\/leu.2011.237","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T17:35:31Z","timestamp":1315589731000},"page":"424-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Regulatory T cells and immunodeficiency in mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.1038","volume":"26","author":[{"given":"T","family":"Krejsgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Odum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Wasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Woetmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,9]]},"reference":[{"key":"BFleu2011237_CR1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768\u20133785.","journal-title":"Blood"},{"key":"BFleu2011237_CR2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","volume":"115","author":"EJ Kim","year":"2005","unstructured":"Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM et al. Immunopathogenesis and therapy of cutaneous T-cell lymphoma. J Clin Invest 2005; 115: 798\u2013812.","journal-title":"J Clin Invest"},{"key":"BFleu2011237_CR3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(08)60420-1","volume":"371","author":"ST Hwang","year":"2008","unstructured":"Hwang ST, Janik JE, Jaffe ES, Wilson WH . Mycosis fungoides and Sezary syndrome. Lancet 2008; 371: 945\u2013957.","journal-title":"Lancet"},{"key":"BFleu2011237_CR4","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","volume":"350","author":"M Girardi","year":"2004","unstructured":"Girardi M, Heald PW, Wilson LD . The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350: 1978\u20131988.","journal-title":"N Engl J Med"},{"key":"BFleu2011237_CR5","first-page":"2212","volume":"95","author":"B Vergier","year":"2000","unstructured":"Vergier B, de MA, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood 2000; 95: 2212\u20132218.","journal-title":"Blood"},{"key":"BFleu2011237_CR6","first-page":"857","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT . Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857\u2013866.","journal-title":"Arch Dermatol"},{"key":"BFleu2011237_CR7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","volume":"46","author":"EC Vonderheid","year":"2002","unstructured":"Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95\u2013106.","journal-title":"J Am Acad Dermatol"},{"key":"BFleu2011237_CR8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1523-1747.ep12398454","volume":"103","author":"BR Vowels","year":"1994","unstructured":"Vowels BR, Lessin SR, Cassin M, Jaworsky C, Benoit B, Wolfe JT et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994; 103: 669\u2013673.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011237_CR9","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0889-8588(03)00109-6","volume":"17","author":"AH Rook","year":"2003","unstructured":"Rook AH, Kuzel TM, Olsen EA . Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 2003; 17: 1435\u20131448, ix.","journal-title":"Hematol Oncol Clin North Am"},{"key":"BFleu2011237_CR10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/1523-1747.ep12363378","volume":"107","author":"CL Berger","year":"1996","unstructured":"Berger CL, Wang N, Christensen I, Longley J, Heald P, Edelson RL . The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol 1996; 107: 392\u2013397.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011237_CR11","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood.V91.11.4331","volume":"91","author":"M Bagot","year":"1998","unstructured":"Bagot M, Echchakir H, Mami-Chouaib F, Delfau-Larue MH, Charue D, Bernheim A et al. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 1998; 91: 4331\u20134341.","journal-title":"Blood"},{"key":"BFleu2011237_CR12","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1200\/JCO.2001.19.23.4322","volume":"19","author":"MH Vermeer","year":"2001","unstructured":"Vermeer MH, van DR, Dukers D, Bekkenk MW, Meijer CJ, Willemze R . CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001; 19: 4322\u20134329.","journal-title":"J Clin Oncol"},{"key":"BFleu2011237_CR13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0190-9622(95)90067-5","volume":"32","author":"RT Hoppe","year":"1995","unstructured":"Hoppe RT, Medeiros LJ, Warnke RA, Wood GS . CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995; 32: 448\u2013453.","journal-title":"J Am Acad Dermatol"},{"key":"BFleu2011237_CR14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/1523-1747.ep12292129","volume":"108","author":"K Asadullah","year":"1997","unstructured":"Asadullah K, Friedrich M, Docke WD, Jahn S, Volk HD, Sterry W . Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma. J Invest Dermatol 1997; 108: 743\u2013747.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011237_CR15","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2004-03-1190","volume":"104","author":"M Wysocka","year":"2004","unstructured":"Wysocka M, Benoit BM, Newton S, Azzoni L, Montaner LJ, Rook AH . Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 2004; 104: 4142\u20134149.","journal-title":"Blood"},{"key":"BFleu2011237_CR16","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.0022-202X.2005.23914.x","volume":"125","author":"JD Bouaziz","year":"2005","unstructured":"Bouaziz JD, Ortonne N, Giustiniani J, Schiavon V, Huet D, Bagot M et al. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients. J Invest Dermatol 2005; 125: 1273\u20131278.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011237_CR17","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","volume":"267","author":"PI Axelrod","year":"1992","unstructured":"Axelrod PI, Lorber B, Vonderheid EC . Infections complicating mycosis fungoides and Sezary syndrome. JAMA 1992; 267: 1354\u20131358.","journal-title":"JAMA"},{"key":"BFleu2011237_CR18","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1172\/JCI108585","volume":"58","author":"S Broder","year":"1976","unstructured":"Broder S, Edelson RL, Lutzner MA, Nelson DL, MacDermott RP, Durm ME et al. The Sezary syndrome: a malignant proliferation of helper T cells. J Clin Invest 1976; 58: 1297\u20131306.","journal-title":"J Clin Invest"},{"key":"BFleu2011237_CR19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0090-1229(79)90038-2","volume":"12","author":"E Kansu","year":"1979","unstructured":"Kansu E, Hauptman SP . Suppressor cell population in Sezary syndrome. Clin Immunol Immunopathol 1979; 12: 341\u2013350.","journal-title":"Clin Immunol Immunopathol"},{"key":"BFleu2011237_CR20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0090-1229(80)90072-0","volume":"17","author":"JE Hopper","year":"1980","unstructured":"Hopper JE, Haren JM . Studies on a Sezary lymphocyte popoulation with T-suppressor activity. Suppression of Ig synthesis of normal peripheral blood lymphocytes. Clin Immunol Immunopathol 1980; 17: 43\u201354.","journal-title":"Clin Immunol Immunopathol"},{"key":"BFleu2011237_CR21","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0145-2126(84)90108-5","volume":"8","author":"F Miedema","year":"1984","unstructured":"Miedema F, Willemze R, Terpstra FG, van Vloten WA, Meijer CJ, Melief CJ . Regulatory activity of neoplastic T cells in Sezary syndrome on in vitro immunoglobulin production. Leuk Res 1984; 8: 873\u2013884.","journal-title":"Leuk Res"},{"key":"BFleu2011237_CR22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/1523-1747.ep12874440","volume":"94","author":"U Reinhold","year":"1990","unstructured":"Reinhold U, Pawelec G, Fratila A, Leippold S, Bauer R, Kreysel HW . Phenotypic and functional characterization of tumor infiltrating lymphocytes in mycosis fungoides: continuous growth of CD4+ CD45R+ T-cell clones with suppressor-inducer activity. J Invest Dermatol 1990; 94: 304\u2013309.","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"BFleu2011237_CR23","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1002\/eji.200737593","volume":"37","author":"S Sakaguchi","year":"2007","unstructured":"Sakaguchi S, Wing K, Miyara M . Regulatory T cells\u2014a brief history and perspective. Eur J Immunol 2007; 37 Suppl 1: S116\u2013S123.","journal-title":"Eur J Immunol"},{"key":"BFleu2011237_CR24","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M . Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151\u20131164.","journal-title":"J Immunol"},{"key":"BFleu2011237_CR25","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4049\/jimmunol.167.3.1245","volume":"167","author":"C Baecher-Allan","year":"2001","unstructured":"Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA . CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245\u20131253.","journal-title":"J Immunol"},{"key":"BFleu2011237_CR26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057\u20131061.","journal-title":"Science"},{"key":"BFleu2011237_CR27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.immuni.2005.01.016","volume":"22","author":"JD Fontenot","year":"2005","unstructured":"Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY . Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22: 329\u2013341.","journal-title":"Immunity"},{"key":"BFleu2011237_CR28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ni909","volume":"4","author":"R Khattri","year":"2003","unstructured":"Khattri R, Cox T, Yasayko SA, Ramsdell F . An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4: 337\u2013342.","journal-title":"Nat Immunol"},{"key":"BFleu2011237_CR29","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/eji.200526189","volume":"35","author":"G Roncador","year":"2005","unstructured":"Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005; 35: 1681\u20131691.","journal-title":"Eur J Immunol"},{"key":"BFleu2011237_CR30","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nature05479","volume":"445","author":"YY Wan","year":"2007","unstructured":"Wan YY, Flavell RA . Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007; 445: 766\u2013770.","journal-title":"Nature"},{"key":"BFleu2011237_CR31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/ni1437","volume":"8","author":"LM Williams","year":"2007","unstructured":"Williams LM, Rudensky AY . Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007; 8: 277\u2013284.","journal-title":"Nat Immunol"},{"key":"BFleu2011237_CR32","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1172\/JCI11679","volume":"106","author":"TA Chatila","year":"2000","unstructured":"Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000; 106: R75\u2013R81.","journal-title":"J Clin Invest"},{"key":"BFleu2011237_CR33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/83784","volume":"27","author":"ME Brunkow","year":"2001","unstructured":"Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA et al. Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27: 68\u201373.","journal-title":"Nat Genet"},{"key":"BFleu2011237_CR34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","volume":"27","author":"CL Bennett","year":"2001","unstructured":"Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20\u201321.","journal-title":"Nat Genet"},{"key":"BFleu2011237_CR35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/83707","volume":"27","author":"RS Wildin","year":"2001","unstructured":"Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27: 18\u201320.","journal-title":"Nat Genet"},{"key":"BFleu2011237_CR36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1172\/JCI25112","volume":"116","author":"R Bacchetta","year":"2006","unstructured":"Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116: 1713\u20131722.","journal-title":"J Clin Invest"},{"key":"BFleu2011237_CR37","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/intimm\/dxh165","volume":"16","author":"H Yagi","year":"2004","unstructured":"Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004; 16: 1643\u20131656.","journal-title":"Int Immunol"},{"key":"BFleu2011237_CR38","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1073\/pnas.0509484103","volume":"103","author":"MA Gavin","year":"2006","unstructured":"Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T-cell development. Proc Natl Acad Sci USA 2006; 103: 6659\u20136664.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2011237_CR39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nri2785","volume":"10","author":"S Sakaguchi","year":"2010","unstructured":"Sakaguchi S, Miyara M, Costantino CM, Hafler DA . FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490\u2013500.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2011237_CR40","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/eji.200737594","volume":"37","author":"U Baron","year":"2007","unstructured":"Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37: 2378\u20132389.","journal-title":"Eur J Immunol"},{"key":"BFleu2011237_CR41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nri2474","volume":"9","author":"J Huehn","year":"2009","unstructured":"Huehn J, Polansky JK, Hamann A . Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? Nat Rev Immunol 2009; 9: 83\u201389.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2011237_CR42","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.4049\/jimmunol.171.11.5678","volume":"171","author":"C Cozzo","year":"2003","unstructured":"Cozzo C, Larkin III J, Caton AJ . Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 2003; 171: 5678\u20135682.","journal-title":"J Immunol"},{"key":"BFleu2011237_CR43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni759","volume":"3","author":"J Shimizu","year":"2002","unstructured":"Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S . Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3: 135\u2013142.","journal-title":"Nat Immunol"},{"key":"BFleu2011237_CR44","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","volume":"203","author":"W Liu","year":"2006","unstructured":"Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701\u20131711.","journal-title":"J Exp Med"},{"key":"BFleu2011237_CR45","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1084\/jem.20060468","volume":"203","author":"N Seddiki","year":"2006","unstructured":"Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693\u20131700.","journal-title":"J Exp Med"},{"key":"BFleu2011237_CR46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.192.2.295","volume":"192","author":"S Read","year":"2000","unstructured":"Read S, Malmstrom V, Powrie F . Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295\u2013302.","journal-title":"J Exp Med"},{"key":"BFleu2011237_CR47","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.immuni.2009.05.002","volume":"30","author":"MA Curotto de Lafaille","year":"2009","unstructured":"Curotto de Lafaille MA, Lafaille JJ . Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009; 30: 626\u2013635.","journal-title":"Immunity"},{"key":"BFleu2011237_CR48","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00018-009-0026-2","volume":"66","author":"CJ Workman","year":"2009","unstructured":"Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DA . The development and function of regulatory T cells. Cell Mol Life Sci 2009; 66: 2603\u20132622.","journal-title":"Cell Mol Life Sci"},{"key":"BFleu2011237_CR49","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.immuni.2009.04.010","volume":"30","author":"EM Shevach","year":"2009","unstructured":"Shevach EM . Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30: 636\u2013645.","journal-title":"Immunity"},{"key":"BFleu2011237_CR50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","volume":"6","author":"W Zou","year":"2006","unstructured":"Zou W . Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295\u2013307.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2011237_CR51","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/blood-2004-06-2181","volume":"105","author":"CL Berger","year":"2005","unstructured":"Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005; 105: 1640\u20131647.","journal-title":"Blood"},{"key":"BFleu2011237_CR52","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/sj.leu.2403965","volume":"19","author":"G Roncador","year":"2005","unstructured":"Roncador G, Garcia JF, Garcia JF, Maestre L, Lucas E, Menarguez J et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia\/lymphoma. Leukemia 2005; 19: 2247\u20132253.","journal-title":"Leukemia"},{"key":"BFleu2011237_CR53","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.leu.2404182","volume":"20","author":"CD Klemke","year":"2006","unstructured":"Klemke CD, Fritzsching B, Franz B, Kleinmann EV, Oberle N, Poenitz N et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 1123\u20131129.","journal-title":"Leukemia"},{"key":"BFleu2011237_CR54","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-0560.2009.01381.x","volume":"37","author":"DA Wada","year":"2010","unstructured":"Wada DA, Wilcox RA, Weenig RH, Gibson LE . Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis. J Cutan Pathol 2010; 37: 535\u2013541.","journal-title":"J Cutan Pathol"},{"key":"BFleu2011237_CR55","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0609.2006.00809.x","volume":"78","author":"C Hallermann","year":"2007","unstructured":"Hallermann C, Niermann C, Schulze HJ . Regulatory T-cell phenotype in association with large cell transformation of mycosis fungoides. Eur J Haematol 2007; 78: 260\u2013263.","journal-title":"Eur J Haematol"},{"key":"BFleu2011237_CR56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1600-0609.2007.00990.x","volume":"80","author":"AH Banham","year":"2008","unstructured":"Banham AH, Brown PJ, Lyne L, Schulze HJ, Hallermann C . Is FOXP3 expressed in cutaneous T-cell lymphomas? Eur J Haematol 2008; 80: 90\u201391.","journal-title":"Eur J Haematol"},{"key":"BFleu2011237_CR57","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/sj.leu.2404913","volume":"21","author":"LM Gjerdrum","year":"2007","unstructured":"Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007; 21: 2512\u20132518.","journal-title":"Leukemia"},{"key":"BFleu2011237_CR58","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.4049\/jimmunol.181.4.2506","volume":"181","author":"M Kasprzycka","year":"2008","unstructured":"Kasprzycka M, Zhang Q, Witkiewicz A, Marzec M, Potoczek M, Liu X et al. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol 2008; 181: 2506\u20132512.","journal-title":"J Immunol"},{"key":"BFleu2011237_CR59","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1182\/blood-2010-05-287664","volume":"117","author":"RA Clark","year":"2011","unstructured":"Clark RA, Shackelton JB, Watanabe R, Calarese A, Yamanaka KI, Campbell JJ et al. High scatter T cells (THS): a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma. Blood 2011; 117: 1966\u20131976.","journal-title":"Blood"},{"key":"BFleu2011237_CR60","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/sj.jid.5700371","volume":"126","author":"MM Tiemessen","year":"2006","unstructured":"Tiemessen MM, Mitchell TJ, Hendry L, Whittaker SJ, Taams LS, John S . Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126: 2217\u20132223.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011237_CR61","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/jid.2009.175","volume":"129","author":"JB Heid","year":"2009","unstructured":"Heid JB, Schmidt A, Oberle N, Goerdt S, Krammer PH, Suri-Payer E et al. FOXP3+CD25- tumor cells with regulatory function in S\u00e9zary syndrome. J Invest Dermatol 2009; 129: 2875\u20132885.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011237_CR62","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1111\/j.1600-0625.2009.00993.x","volume":"19","author":"AC Knol","year":"2010","unstructured":"Knol AC, Quereux G, Brocard A, Ballanger F, Khammari A, Nguyen JM et al. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene. Exp Dermatol 2010; 19: e95\u2013e102.","journal-title":"Exp Dermatol"},{"key":"BFleu2011237_CR63","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1600-0560.2007.00969.x","volume":"35","author":"GJ Solomon","year":"2008","unstructured":"Solomon GJ, Magro CM . Foxp3 expression in cutaneous T-cell lymphocytic infiltrates. J Cutan Pathol 2008; 35: 1032\u20131039.","journal-title":"J Cutan Pathol"},{"key":"BFleu2011237_CR64","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1365-2133.2008.08504.x","volume":"158","author":"T Fujimura","year":"2008","unstructured":"Fujimura T, Okuyama R, Ito Y, Aiba S . Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides. Br J Dermatol 2008; 158: 1256\u20131263.","journal-title":"Br J Dermatol"},{"key":"BFleu2011237_CR65","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clim.2009.08.016","volume":"133","author":"V Rao","year":"2009","unstructured":"Rao V, Saunes M, Jorstad S, Moen T . Cutaneous T cell lymphoma and graft-versus-host disease: a comparison of in vivo effects of extracorporeal photochemotherapy on Foxp3+ regulatory T cells. Clin Immunol 2009; 133: 303\u2013313.","journal-title":"Clin Immunol"},{"key":"BFleu2011237_CR66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/039463200902200212","volume":"22","author":"P Quaglino","year":"2009","unstructured":"Quaglino P, Comessatti A, Ponti R, Peroni A, Mola F, Fierro MT et al. Reciprocal modulation of circulating CD4+CD25+bright T cells induced by extracorporeal photochemotherapy in cutaneous T-cell lymphoma and chronic graft-versus-host-disease patients. Int J Immunopathol Pharmacol 2009; 22: 353\u2013362.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"BFleu2011237_CR67","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1080\/10428190802064917","volume":"49","author":"E Capriotti","year":"2008","unstructured":"Capriotti E, Vonderheid EC, Thoburn CJ, Wasik MA, Bahler DW, Hess AD . Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma 2008; 49: 1190\u20131201.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2011237_CR68","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/leu.2008.224","volume":"22","author":"T Krejsgaard","year":"2008","unstructured":"Krejsgaard T, Gjerdrum LM, Ralfkiaer E, Lauenborg B, Eriksen KW, Mathiesen AM et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome. Leukemia 2008; 22: 2230\u20132239.","journal-title":"Leukemia"},{"key":"BFleu2011237_CR69","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.jid.5700029","volume":"126","author":"HK Wong","year":"2006","unstructured":"Wong HK, Wilson AJ, Gibson HM, Hafner MS, Hedgcock CJ, Berger CL et al. Increased expression of CTLA-4 in malignant T cells from patients with mycosis fungoides\u2014cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126: 212\u2013219.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011237_CR70","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2133.2003.05224.x","volume":"148","author":"E Papadavid","year":"2003","unstructured":"Papadavid E, Economidou J, Psarra A, Kapsimali V, Mantzana V, Antoniou C et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 2003; 148: 709\u2013718.","journal-title":"Br J Dermatol"},{"key":"BFleu2011237_CR71","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/blood-2002-01-0231","volume":"100","author":"M Wysocka","year":"2002","unstructured":"Wysocka M, Zaki MH, French LE, Chehimi J, Shapiro M, Everetts SE et al. Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 2002; 100: 3287\u20133294.","journal-title":"Blood"},{"key":"BFleu2011237_CR72","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.V92.1.252.413k08_252_258","volume":"92","author":"U Dobbeling","year":"1998","unstructured":"Dobbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G . Interleukin-15 is an autocrine\/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998; 92: 252\u2013258.","journal-title":"Blood"},{"key":"BFleu2011237_CR73","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1172\/JCI115920","volume":"90","author":"A Dalloul","year":"1992","unstructured":"Dalloul A, Laroche L, Bagot M, Mossalayi MD, Fourcade C, Thacker DJ et al. Interleukin-7 is a growth factor for Sezary lymphoma cells. J Clin Invest 1992; 90: 1054\u20131060.","journal-title":"J Clin Invest"},{"key":"BFleu2011237_CR74","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/eji.201040531","volume":"40","author":"F Simonetta","year":"2010","unstructured":"Simonetta F, Chiali A, Cordier C, Urrutia A, Girault I, Bloquet S et al. Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur J Immunol 2010; 40: 2528\u20132538.","journal-title":"Eur J Immunol"},{"key":"BFleu2011237_CR75","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.4049\/jimmunol.180.7.4785","volume":"180","author":"J Du","year":"2008","unstructured":"Du J, Huang C, Zhou B, Ziegler SF . Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3. J Immunol 2008; 180: 4785\u20134792.","journal-title":"J Immunol"},{"key":"BFleu2011237_CR76","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1053\/hupa.2000.20370","volume":"31","author":"KF Izban","year":"2000","unstructured":"Izban KF, Ergin M, Qin JZ, Martinez RL, Pooley RJ JR, Saeed S et al. Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol 2000; 31: 1482\u20131490.","journal-title":"Hum Pathol"},{"key":"BFleu2011237_CR77","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2005-06-2536","volume":"107","author":"A Sors","year":"2006","unstructured":"Sors A, Jean-Louis F, Pellet C, Laroche L, Dubertret L, Courtois G et al. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 2006; 107: 2354\u20132363.","journal-title":"Blood"},{"key":"BFleu2011237_CR78","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1158\/1078-0432.CCR-07-1419","volume":"14","author":"A Sors","year":"2008","unstructured":"Sors A, Jean-Louis F, Begue E, Parmentier L, Dubertret L, Dreano M et al. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents. Clin Cancer Res 2008; 14: 901\u2013911.","journal-title":"Clin Cancer Res"},{"key":"BFleu2011237_CR79","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1182\/blood-2008-09-181024","volume":"113","author":"T Krejsgaard","year":"2009","unstructured":"Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Kneitz H, Eriksen KW, Lovato P et al. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood 2009; 113: 5896\u20135904.","journal-title":"Blood"},{"key":"BFleu2011237_CR80","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1038\/jid.2009.290","volume":"129","author":"RA Clark","year":"2009","unstructured":"Clark RA . Regulation gone wrong: a subset of Sezary patients have malignant regulatory T cells. J Invest Dermatol 2009; 129: 2747\u20132750.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011237_CR81","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jaad.2009.06.082","volume":"62","author":"C Schlapbach","year":"2010","unstructured":"Schlapbach C, Ochsenbein A, Kaelin U, Hassan AS, Hunger RE, Yawalkar N . High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. J Am Acad Dermatol 2010; 62: 995\u20131004.","journal-title":"J Am Acad Dermatol"},{"key":"BFleu2011237_CR82","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.immuni.2009.05.001","volume":"30","author":"L Zhou","year":"2009","unstructured":"Zhou L, Chong MM, Littman DR . Plasticity of CD4+ T-cell lineage differentiation. Immunity 2009; 30: 646\u2013655.","journal-title":"Immunity"},{"key":"BFleu2011237_CR83","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.coi.2010.08.004","volume":"22","author":"S Hori","year":"2010","unstructured":"Hori S . Developmental plasticity of Foxp3+ regulatory T cells. Curr Opin Immunol 2010; 22: 575\u2013582.","journal-title":"Curr Opin Immunol"},{"key":"BFleu2011237_CR84","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1073\/pnas.0811556106","volume":"106","author":"N Komatsu","year":"2009","unstructured":"Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S . Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009; 106: 1903\u20131908.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2011237_CR85","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/jid.2011.27","volume":"131","author":"T Krejsgaard","year":"2011","unstructured":"Krejsgaard T, Ralfkiaer U, Clasen-Linde E, Eriksen KW, Kopp KL, Bonefeld CM et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3\/Stat3 signaling pathway. J Invest Dermatol 2011; 131: 1331\u20131338.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011237_CR86","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/sj.jid.5700121","volume":"126","author":"PT Walsh","year":"2006","unstructured":"Walsh PT, Benoit BM, Wysocka M, Dalton NM, Turka LA, Rook AH . A role for regulatory T cells in cutaneous T-cell lymphoma; induction of a CD4 + CD25 + Foxp3+ T-cell phenotype associated with HTLV-1 infection. J Invest Dermatol 2006; 126: 690\u2013692.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011237_CR87","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood-2006-04-017863","volume":"109","author":"A Woetmann","year":"2007","unstructured":"Woetmann A, Lovato P, Eriksen KW, Krejsgaard T, Labuda T, Zhang Q et al. Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood 2007; 109: 3325\u20133332.","journal-title":"Blood"},{"key":"BFleu2011237_CR88","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.2008.08612.x","volume":"159","author":"R Talpur","year":"2008","unstructured":"Talpur R, Bassett R, Duvic M . Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 2008; 159: 105\u2013112.","journal-title":"Br J Dermatol"},{"key":"BFleu2011237_CR89","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.leu.2403385","volume":"18","author":"VH Sommer","year":"2004","unstructured":"Sommer VH, Clemmensen OJ, Nielsen O, Wasik M, Lovato P, Brender C et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004; 18: 1288\u20131295.","journal-title":"Leukemia"},{"key":"BFleu2011237_CR90","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.1073\/pnas.93.17.9148","volume":"93","author":"Q Zhang","year":"1996","unstructured":"Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC et al. Activation of Jak\/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996; 93: 9148\u20139153.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2011237_CR91","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/sj.leu.2404350","volume":"20","author":"T Krejsgaard","year":"2006","unstructured":"Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW et al. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006; 20: 1759\u20131766.","journal-title":"Leukemia"},{"key":"BFleu2011237_CR92","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R . STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798\u2013809.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2011237_CR93","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1749-6632.2001.tb03708.x","volume":"941","author":"M Bagot","year":"2001","unstructured":"Bagot M, Nikolova M, Schirm-Chabanette F, Wechsler J, Boumsell L, Bensussan A . Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas. Ann NY Acad Sci 2001; 941: 31\u201338.","journal-title":"Ann NY Acad Sci"},{"key":"BFleu2011237_CR94","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1073\/pnas.91.13.6002","volume":"91","author":"ME Kadin","year":"1994","unstructured":"Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D . Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 6002\u20136006.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2011237_CR95","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1158\/0008-5472.CAN-04-1253","volume":"64","author":"DR van","year":"2004","unstructured":"van DR, Dijkman R, Vermeer MH, Out-Luiting JJ, van der Raaij-Helmer EM, Willemze R et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 2004; 64: 5578\u20135586.","journal-title":"Cancer Res"},{"key":"BFleu2011237_CR96","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood.V94.8.2854.420k07_2854_2861","volume":"94","author":"WP Schiemann","year":"1999","unstructured":"Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF . A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood 1999; 94: 2854\u20132861.","journal-title":"Blood"},{"key":"BFleu2011237_CR97","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V97.4.1056","volume":"97","author":"C Brender","year":"2001","unstructured":"Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, Wasik M et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 2001; 97: 1056\u20131062.","journal-title":"Blood"},{"key":"BFleu2011237_CR98","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.leu.2403610","volume":"19","author":"C Brender","year":"2005","unstructured":"Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C et al. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 2005; 19: 209\u2013213.","journal-title":"Leukemia"},{"key":"BFleu2011237_CR99","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/1523-1747.ep12611877","volume":"99","author":"BR Vowels","year":"1992","unstructured":"Vowels BR, Cassin M, Vonderheid EC, Rook AH . Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99: 90\u201394.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011237_CR100","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","volume":"94","author":"AH Rook","year":"1999","unstructured":"Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902\u2013908.","journal-title":"Blood"},{"key":"BFleu2011237_CR101","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2006.06.038","volume":"55","author":"M Duvic","year":"2006","unstructured":"Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 2006; 55: 807\u2013813.","journal-title":"J Am Acad Dermatol"},{"key":"BFleu2011237_CR102","doi-asserted-by":"crossref","unstructured":"Kantekure K, Yang Y, Raghunath P, Schaffer A, Woetmann A, Zhang Q et al. Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma (CTCL)\/mycosis fungoides (MF). Am J Dermatopath. In press 2011.","DOI":"10.1097\/DAD.0b013e31821c35cb"},{"key":"BFleu2011237_CR103","first-page":"2682","volume":"7","author":"X Ni","year":"2001","unstructured":"Ni X, Hazarika P, Zhang C, Talpur R, Duvic M . Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 2001; 7: 2682\u20132692.","journal-title":"Clin Cancer Res"},{"key":"BFleu2011237_CR104","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2133.2000.03656.x","volume":"143","author":"O Zoi-Toli","year":"2000","unstructured":"Zoi-Toli O, Vermeer MH, de VE, Van BP, Meijer CJ, Willemze R . Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 2000; 143: 313\u2013319.","journal-title":"Br J Dermatol"},{"key":"BFleu2011237_CR105","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood-2003-04-1044","volume":"102","author":"N Yawalkar","year":"2003","unstructured":"Yawalkar N, Ferenczi K, Jones DA, Yamanaka K, Suh KY, Sadat S et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003; 102: 4059\u20134066.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011237","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T06:22:11Z","timestamp":1712816531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,9]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["BFleu2011237"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.237","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,9]]},"assertion":[{"value":"6 April 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}